

Special Issue

Immunotherapy in Melanoma: Recent Advances and Future Directions (2nd Edition)

Message from the Guest Editors

Looking beyond the pandemic, immune-checkpoint inhibitors (ICIs) continue to offer long-term remission in melanoma, either in an adjuvant or a metastatic setting. At the same time, the development of new immunotherapeutic agents (e.g., relatlimab and bempegaldesleukin) or combinatorial regimens (e.g., immune/targeted combinations, intralesional infusions and ICIs) and the identification of intratumoral or circulating biomarkers continue to open new horizons and produce new questions for immune-mediated treatments. Issues such as the duration and the exact dose of anti-PD1/anti-PDL1 and anti-CTLA4 agents in metastatic and locoregional disease, the stage of early melanoma that should be treated with ICIs and the potential of intralesional infusions are still under consideration and an open field for debate. To this end, this Special Issue of *Cancers* aims to explore the constantly remodeled area of immunotherapy in melanoma management in the post-COVID-19 era and tries to recap where we are and where we are going in terms of the knowledge on immune-mediated therapies in melanoma.

Guest Editors

Dr. Dimitrios C. Ziogas

First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Prof. Dr. Helen Gogas

First Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Deadline for manuscript submissions

closed (31 August 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/218272

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)